The Jacksonville Jaguars announced two additions to the coaching staff on Wednesday. Mathieu Araujo will take over as the defensive pass game coordinator, and Brian Picucci will be the run game ...

Virtual Boy - Nintendo Classics launches next month, but its most interesting new feature and some important games won't be there at release. This was revealed by a new overview trailer released by ...

Going into the offseason, offensive line stood out as one of the top needs for Missouri. On Wednesday and Thursday, Missouri added experienced players to the group. First was Luke Work, coming over ...

MAGA reacts to new video from deadly Minneapolis ICE shooting Food pyramid faces scrutiny as Ben Carson reveals why Americans don't have to eat meat Wondering if you should get a flu shot? Here’s what ...

A nearly intact Geran-2, landed upright on the ground, was found with a 9K333 Verba Man-Portable Air Defense System (MANPADS) mounted on the top. A month after a Russian Geran-2 one-way attack (OWA) ...

As part of the annual review of the Penny Interval Program (“Penny Program”), MIAX Options, MIAX Pearl Options, MIAX Emerald Options, and MIAX Sapphire Options will make changes to the securities ...

The Devils Youth Foundation announced today the additions of Kate Madigan and Nicole Zajac to its Board of Directors. In their respective roles, Madigan and Zajac will provide guidance and assist with ...

AI stocks have been some of the best investment opportunities, and these two growth stocks can continue the trend. Palantir is signing massive deals for its AI software while boosting margins.

Nintendo has announced its Nintendo Switch Online additions for December, which are for all the N64-era 3D platformer fans out there. On December 17, Rayman 2: The Great Escape and Tonic Trouble are ...

(RTTNews) - Q32 Bio Inc. (QTTB) has sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics, Inc. (AKBA), securing upfront and milestone payments that will extend its cash runway into the ...

Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement inhibitor ADX-097, paying $7 million upfront for an asset that forms the centerpiece of its new rare kidney disease ...